Association between the Epstein-Barr virus and Hodgkin's lymphoma in the north-eastern part of Hungary: Effects on therapy and survival

Katalin Keresztes, Zsofia Miltenyi, Beata Bessenyei, Zoltan Beck, Zoltan Szollosi, Zoltan Nemes, Eva Olah, Arpad Illes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This retrospective study included 109 patients with Hodgkin's lymphoma (HL; 45 females, 64 males). In 47 of the 109 HL patients (43%), immunohistochemical analysis of their formalin-fixed, paraffin-embedded histologie samples revealed Epstein-Barr virus (EBV) by latent membrane protein (LMP) 1. The highest virus association (50%) was found with the mixed cellularity histologic subtype, especially in patients aged 11-20 and >50 years. Virus positivity in nodular sclerosis was 35% (negative cases accumulated in patients aged 15-30 years). Regarding clinical stages, histologic subtypes, general symptoms, treatments employed and response to treatment, the EBV-positive group was not significantly different from the virus-negative group. During the mean follow-up time of 83 months (9-300 months), the overall or event-free survival of EBV-negative patients was more favorable than that of EBV-positive patients, although the difference was not significant (p = 0.16 and p = 0.24, respectively). EBV infection may be involved in the pathogenesis of HL in our Hungarian study cohort, but it does not significantly affect clinical symptoms, therapeutic results or complete and event-free survival of HL patients.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
JournalActa Haematologica
Volume116
Issue number2
DOIs
Publication statusPublished - Aug 1 2006

Keywords

  • Epstein-Barr
  • Hodgkin's lymphoma
  • Survival

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Association between the Epstein-Barr virus and Hodgkin's lymphoma in the north-eastern part of Hungary: Effects on therapy and survival'. Together they form a unique fingerprint.

  • Cite this